Mei‐Hui Hsu

2.3k citations
33 papers · 1.8k indexed · h-index 24
Topics
Pharmacogenetics and Drug Metabolism (14 papers)Drug Transport and Resistance Mechanisms (9 papers)Peroxisome Proliferator-Activated Receptors (9 papers)

In The Last Decade

Mei‐Hui Hsu

32 papers receiving 1.8k citations

Peers

Mei‐Hui Hsu
Comparison fields: 5 of 94
  • Molecular Biology 1.0k
  • Pharmacology 679
  • Biochemistry 435
  • Oncology 349
  • Physiology 254
Replace Üzen Savas with:
Üzen Savas United States
Richard T. Okita United States
Y. Yasukochi Japan
M J Coon United States
Dylan P. Hartley United States
Thomas M. Guenthner United States
Linda M. Reik United States
Fred K. Friedman United States
Taro E. Akiyama United States
Masayuki Komori Japan
Mei‐Hui Hsu relative to Üzen Savas United States Üzen Savas's profile →
Citations per field
00.5×1.5×1.8×
Üzen Savas · 1×
Citations per year

Countries citing papers authored by Mei‐Hui Hsu

Since Specialization
Citations

This map shows the geographic impact of Mei‐Hui Hsu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei‐Hui Hsu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei‐Hui Hsu more than expected).

Fields of papers citing papers by Mei‐Hui Hsu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei‐Hui Hsu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei‐Hui Hsu. The network helps show where Mei‐Hui Hsu may publish in the future.

Co-authorship network of co-authors of Mei‐Hui Hsu

This figure shows the co-authorship network connecting the top 25 collaborators of Mei‐Hui Hsu. A scholar is included among the top collaborators of Mei‐Hui Hsu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei‐Hui Hsu. Mei‐Hui Hsu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 2
3 1
4 8
5 34
6 19
7 36
8 25
9 39
10 23
11 111
12 37
13 43
14 66
15 39
16 161
17 59
18 7
19 32
20 40

About Mei‐Hui Hsu

Mei‐Hui Hsu is a scholar working on Pharmacology, Biochemistry and Oncology, having authored 33 papers that have together received 1.8k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (14 papers), Drug Transport and Resistance Mechanisms (9 papers) and Peroxisome Proliferator-Activated Receptors (9 papers). The work is most often cited by research in Pharmacology (679 citations), Biochemistry (435 citations) and Molecular Biology (1.0k citations). Mei‐Hui Hsu has collaborated with scholars based in United States, Taiwan and United Kingdom. Frequent co-authors include Eric F. Johnson, Keith J. Griffin, Üzen Savas, C.D. Stout, A. Scott Muerhoff, L. Ashley Cowart, John R. Falck, Jorge H. Capdevila, Shouzuo Wei and Wan‐Ping Hu. Their work appears in journals such as Journal of Biological Chemistry, The FASEB Journal and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026